Fifteen elderly hypertensives aged fifty-nine to seventy-four years received captopril either as a monotherapy (group I, n=7) or as an addition to other antihypertensive drugs (group II, n=8) for twelve to fourteen months. Both the mean supine and erect blood pressure fell from 173.3 ± 3.4/93.3 ± 6.6 to 143.3±3.4/78.3±1.7 and from 166.7+8.6/98.3+4.4 to 146.7±12.0/85.0±2.9 mm Hg, respectively, in group I, and from 165.6±10.5/104.9±4.4 to 128.8±4.7/84.1±1.7 and from 154.0±10.1/107.8±3.3 to 126.3±6.0/88.8±1.2 mm Hg, respectively, in group II. There was a slight but insignificant reduction in pulse rate and body weight. Side effects were minimal. All patients experienced a sense of well-being. There was no impairment of renal function in most patients and no reduction in serum K. This study suggests that, in elderly hypertensives, captopril reduces blood pressure safely and effectively without impairing perfusion to the brain, heart, and kidneys and without causing edema or hypokalemia.
Get full access to this article
View all access options for this article.
References
1.
Ostfeld AM: Elderly hypertensive patient. Epidemiologic review. NY State J Med78:1125, 1978.
2.
Kirkendall WH , Hammond JJ: Hypertension in the elderly. Arch Intern Med140:1155, 1980.
3.
Kannel WB, Gordon T., Schwartz MJ: Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham Study. Am J Cardiol27:335, 1971.
4.
Hypertension Detection and Follow-up Program. II.Mortality by race, sex and age. JAMA242:2572, 1979.
5.
Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program. III. Reduction in strike incidence among persons with high blood pressure. JAMA247:633, 1982.
6.
Chobanian AV : Treatment of the elderly hypertensive patient . Am J Med77(2B):22, 1984.
7.
Buhler FR: Age and cardiovascular response adaptation. Determinants of an antihypertensive treatment concept primarily based on beta-blockers and calcium entry blockers . Hypertension (supp. III):III-94, 1983.
8.
Fitzpatrick MA, Julius S.: Hemodynamic effects of angiotensin-converting enzyme inhibitors in essential hypertension: A review. J Cardiovasc Pharmacol7(supp. I):S-35, 1985 .
9.
Weinberger M. : Blood pressure and metabolic responses to hydrochlorothiazide, captopril and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol7(supp. I):S-52, 1985.
10.
Simon AC, et al: Effects of acute and chronic angiotensin converting enzyme inhibition on large arteries in human hypertension. J Cardiovasc Pharmacol7 (supp. I):S-45, 1985.
11.
Jenkins AC, Knill JR, Dreslinski GR: Captopril in the treatment of the elderly hypertensive patient. Arch Intern Med145:2020, 1985.
12.
Paulson OB, et al: Cerebral blood flow in patients with congestive heart failure treated with captopril. Am J Med76(5B):91, 1984 .
13.
Who: Report of a WHO Expert Committee on hypertension: WHO Technical Report Series , Geneva, 1979.
14.
Cody RJ, et al: Cardiovascular reflexes during long-term converting enzyme inhibition and sodium depletion: The response to tilt in hypertensive patients. Am J Med71:422, 1981.
15.
Tarazi RC, et al: Hemodynamic and volume changes associated with captopril. Hypertension2:576, 1980.
16.
Bulpitt CJ, Fletcher AE: Quality of life in hypertensive patients on different antihypertensive treatments: Rationale for methods employed in a multicenter randomized controlled trial . J Cardiovasc Pharmacol7(supp. I):S-137, 1985.
17.
Leary WP, et al: Effects of captopril, hydrochlorothiazide and their combination on timed urinary excretion of water and solutes. J Cardiovasc Pharmacol7 (supp. I):S-56, 1985 .
18.
Vidt DG, Bravo EL, Fouad FM: Captopril. N Engl J Med306:214, 1982.
19.
Heel RC, et al: Captopril: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs20:409, 1980.
